Following the cloning of fusion cDNAs resulting from the translocation, several investigators have employed reverse-transcription polymerase chain reaction (RT-PCR) Twenty patients with APL in long-term remission after BMT were analyzed for the presence of the PML-RAR␣ analysis as a diagnostic laboratory test and for evaluation of minimal residual disease (MRD).
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Southern blot conditions and genomic probes to explore etoposide were administered followed by autograft in 10 patients (autologous BMT in four cases, peripheral stem the PML and RAR␣ genes have been reported elsewhere. 17 Clinical information on these patients is provided in cell transplantation (PBSCT) in six cases) or allogeneic BMT in 10 patients, respectively. Until 1990, hemato- Tables 1 and 2 . They received intensive remission induction chemotherapy with an anthracycline and cytosine arabpoietic precursors were obtained from iliac crests and subsequently, from peripheral blood, except in patient A8, inoside except four patients who received ATRA 45 mg/m 2 /day orally until CR, as well as first treatment in whom aphereses were not performed because of her low weight. In the case of PBSCT, G-CSF was used as (patients A6 and A9), and/or for reinduction after first relapse (patients A9, B7 and B9). Afterwards one, two or the priming agent. The conditioning regimen comprised cyclophosphamide three courses of consolidation/intensification chemotherapy with the same agents or high-dose cytosine arabinoside and (120 mg/kg) plus 13.2 Gy of fractionated total body irradiation delivered in eight fractions of 165 cGy each, we could detect the presence of PML-RAR␣ fusion gene in the presence of less than 0.1 ng total RNA, which repor cyclophosphamide plus 9 Gy of total body irradiation delivered in one session. Two patients received cyclophosresents a final dilution between 10 −4 and 10 −5 (data not shown). phamide (120 mg/kg) plus busulfan 16 mg/kg. For prophylaxis against GVHD, two patients received methotrexate, six patients cyclosporine at standard dose and two patients
Results of RT-PCR studies cyclosporine beginning at a dose of 1.5 mg/kg/24 h plus methotrexate (Table 2) .
A total number of 60 samples were examined by both RT-PCR protocols 1 to 130 months after transplantation (median 18 months) with a median number of three samples RNA isolation per patient (range two to six). The results obtained for each sample are depicted in Figure 1 . Mononuclear cells from bone marrow samples were isolated by Ficoll-Hypaque centrifugation. Specimens were Eight patients were studied just prior to conditioning regimen. In patients B10, A8 and A9 no fusion gene tranobtained with the informed consent of patients. Total RNA was extracted by acid guanidinium thiocyanate-phenolscripts were detected before and after transplant. Patients A7 and B9 showed PML-RAR␣ transcripts before transchloroform method as described by Chomczynski and Sacchi. 18 Any cell sample was divided into at least two aliquots plantation and were persistently PCR-positive in samples tested monthly after transplant. After 7 and 3 months and extracted separately on two different occasions.
respectively in CR, they presented cytogenetic and clinical relapses.
In vitro amplification of PML-RAR␣ transcript
Patients B7 and A10 showed a fusion gene transcript before, but not after allogeneic BMT and PBSCT, respectReverse transcription (RT) was performed on 1 g of total RNA, after heating at 70°C for 5 min, with random hexively. In patient B8, RT-PCR was positive before and 1 month after allogeneic BMT, but became negative 2 months amers as reaction primer. The reaction was carried out at 42°C for 1 h in the presence of 12 units of AMV reverse after transplantation and CR continued. Currently, the other 12 cases not studied before contranscriptase (Boerhinger, Mannheim, West Germany). Five microliters of RT products were used for two rounds ditioning regimen are in continuous CR. In these patients, of polymerase chain reaction (PCR) amplification of the PML-RAR␣ fusion transcripts using two different protocols as previously described by Borrow et al 8 and Biondi et al.
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Amplification of normal RAR␣ transcripts was performed to assess RNA integrity as previously described.
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The second-round PCR product (15 l) was migrated in 1.5% agarose gel containing 1 g/ml ethidium bromide, photographed, transferred onto nylon membranes, hybridized with a 5′ end-labeled oligoprobe, and autoradiographed. The sequence information to synthesize the probes was taken from the published literature.
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Contamination was avoided by strict technical methods. Two negative controls (one with non-APL RNA and one without RNA) and one positive control APL sample were included in each experiment. Confirmation of the results was assessed by performing the RT-PCR at least twice for each sample with both amplification protocols.
Results
Clinical outcomes of the APL patients considered in this study are given in Table 2 . Eighteen of the 20 patients are alive and in CR with a median follow-up of 51.5 months (range 11-137 months). Two patients (B9 and A7) died from relapse at +3 and +7 months, respectively.
Sensitivity determination
To determine the sensitivity of the RT-PCR amplification as described in Materials and methods. With both methods, no PML-RAR␣ transcripts were visible throughout their the complete elimination of the Philadelphia-positive clone, but sometimes it is only capable of preventing its expanpost-BMT courses.
sion. 29 The other two patients (B9 and A7) were not in CR before transplant. Both of them remained PCR-positive Discussion after transplantation until disease recurrence, and appear to represent individuals in whom the ablative regimen did not Recently, in vitro amplification of tumor-specific fusion transcripts by RT-PCR has been applied to the detection of successfully impair the proliferation of malignant cells. Autologous BMT is not an effective treatment when the MRD. Although the availability for diagnosis at a molecular level has been well established, there is disagreement patient is not in complete remission, although in the case of patient A7 the partial remission (7% of blast cells) was as to clinical significance of MRD. Fusion transcripts detected by RT-PCR have not always predicted relapse in a coincidental finding just before conditioning. One can speculate that these patients were already refractory to the near future in chronic myeloid leukemia (CML) with t(9;22) and AML with t(8;21). [19] [20] [21] Although residual dischemotherapy before transplant and therefore their leukemia cells were no more reduced by the subsequent ablative ease studies in CML have mainly been reported in relation to the outcome of allogeneic BMT, other investigators have regimen. This subset of patients, who are more likely to relapse after transplant, could benefit from additional theralso reported that neither PCR positivity in patients undergoing interferon therapy nor autologous BMT is apy with new drugs before transplantation or alternative conditioning regimens. necessarily associated with immediate disease recurrence. 22, 23 While the best post-induction treatment in APL is defined, and monitoring of MRD is applied to MRDIn contrast, several recent studies indicate that molecular monitoring of PML-RAR␣ fusion transcripts in oriented individualized therapy in APL, it is clear that the PML-RAR␣ RT-PCR assay is a useful prognostic tool in APL patients may be useful in predicting relapse and in identifying patients who need further antileukemic the management of these patients after transplantation. The persistent detection of the fusion gene transcript after allotherapy. [10] [11] [12] [13] [14] [15] 24, 25 All these studies demonstrate persistence of the PML-RAR␣ fusion transcript in APL patients after or autografts is associated with subsequent relapse. In contrast, persistently PML-RAR␣ negative patients are prob-CR is achieved with ATRA. However the great majority of these patients convert to RT-PCR negative after consoliably cured. Our results also suggest that transplantation must be indicated in CR patients if a positive RT-PCR dation chemotherapy. Moreover, patients with persistently positive RT-PCR results or patients who convert to RTremains after treatment with ATRA plus chemotherapy. PCR positivity after a negative result are at great risk of relapse.
Our results strengthen further the clinical relevance ofsurvival, some of whom had received BMT. 
